Arbutus trades higher as Q3 net loss narrows, revenue grows on license deal

Nov. 09, 2022 12:26 PM ETArbutus Biopharma Corporation (ABUS)By: Ravikash, SA News Editor2 Comments

Rolled newspaper with the headline Quarterly Results


Arbutus Biopharma (NASDAQ:ABUS) stock was trading in the green on Wednesday following its Q3 results.

Total revenue grew +78.1% Y/Y to $5.95M, but missed analysts estimates.

The company said the increase was mainly due to $2.3M of revenue recognition from

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.